Curated coverage for journavax with top developments, timeline context, and connected threads.
Suzetrigine (Journavax) was FDA-approved in January 2025 and is now reshaping pain management. Here is what it is, how it works differently from opioids, and who it could help.
EuroBulletin24 Editorial Desk | Linked source